Project Grant R01CA313241
Award Date 9/1/26
Completion Date 8/31/29
Dollars Obligated $2.5M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Irwindale, CA 91010, USA
Similar Awards
- The National Cancer Institute awarded Baylor College of Medicine $440,505 on August 10, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate associations between ambient heat and ultraviolet radiation exposure and childhood acute lymphoblastic leukemia (ALL), including molecular alterations in germline and somatic samples. The project, titled RHECALL: Radiation and Heat in Childhood Acute Lymphoblastic Leukemia, will characterize associations between heat and...
- The National Cancer Institute (NCI) awarded a $483,110 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Beckman Research Institute of the City of Hope to conduct research on the functional role of PAX5 mutations in B-cell acute lymphoblastic leukemia (B-ALL). The 5-year project aims to systematically dissect the mechanisms by which PAX5 mutations, which occur in over 10% of B-ALL cases, contribute to disease initiation and progression. The research will use orthogonal...
- The National Cancer Institute awarded $633,126 to Beckman Research Institute of the City of Hope on July 20, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the role of PUS1-mediated mRNA pseudouridine modification in acute myeloid leukemia pathogenesis. The project will define the oncogenic role of PUS1 in AML pathogenesis and elucidate how PUS1-mediated mRNA pseudouridine modification promotes leukemogenesis through post-transcriptional regulation of gene...
- The National Cancer Institute awarded Cincinnati Children's Hospital Medical Center $533,245 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop strategies to eradicate leukemia-initiating cells through investigation of protein glutathionylation regulation. The award supports research examining how post-translational modification of proteins through glutathionylation regulates oxidative phosphorylation in acute myeloid leukemia cells and leukemia-initiating cells,...
- The National Cancer Institute awarded The Regents Of The University Of Colorado (University of Colorado-Denver) $706,866 on July 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to optimize FLT3-targeted and menin-modulated chimeric antigen receptor (CAR) T cell immunotherapies against KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL) and prevent treatment-resistant relapse and lineage switch to acute myeloid leukemia. The recipient will develop best-in-class...
- The National Cancer Institute awarded Cincinnati Children's Hospital Medical Center $522,196 on July 20, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate non-canonical BRAF mutations in acute myeloid leukemia development and therapeutic response. The recipient will conduct research to delineate how BRAF mutations contribute to leukemogenesis, disease phenotype, and therapeutic resistance in AML patients who exhibit dismal survival outcomes regardless of treatment...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded Albert Einstein College of Medicine $431,970 under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, to investigate combination approaches to acute myeloid leukemia targeting both CD123-directed NK cell engagers and BCL-2 inhibition through venetoclax. The research will employ dynamic BH3 profiling to probe mitochondrial priming mechanisms and test whether...
- The National Cancer Institute awarded the University of Chicago $547,740 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to define the molecular mechanisms by which the MLL1 histone modification complex and the long noncoding RNA HOTTIP interact in acute myeloid leukemia pathogenesis. The research examines whether non-specific RNA binding to the WDR5 subunit of the MLL1 complex inhibits the complex's histone methyltransferase activity and whether the RBBP5...
- The National Cancer Institute, a division of the Department of Health and Human Services, awarded the University of Illinois $422,649 as a Project Grant (R21CA303745) on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396). The award funds research into racial disparities in acute myeloid leukemia (AML) treatment outcomes. The study examines whether NPM1 mutant status determines FOXM1 cytoplasmic localization and inactivation in primary bone marrow samples from Black AML...
- The National Cancer Institute awarded the University of Oklahoma $658,322 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to evaluate inherited genetic variation and clinical outcomes among children and adolescents treated for acute myeloid leukemia. Performance runs through April 30, 2028, at the University of Oklahoma Health Sciences Center in Oklahoma City, Oklahoma. The research examines how germline genetic polymorphisms influence treatment response...